On November 20, 2025, the FDA approved Accord BioPharma’s denosumab biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu), which reference Amgen’s PROLIA® and…
Read More →
A federal bankruptcy court on November 18 formally approved Purdue’s $7.4 billion Chapter 11 plan to settle thousands of opioid-related…
Read More →
The Data Stream podcast dives deep into the fast-moving currents of data, technology, and the law. Presented by BakerHostetler’s Digital…
Read More →
The rise in tokenization is transforming the financial landscape, allowing for more efficient and accessible transactions. Differing regulatory regimes across…
Read More →
Beginning on October 20, 2025, recently confirmed United States Patent and Trademark Office (USPTO) Director John A. Squires met with…
Read More →
Die europäische Finanzwirtschaft steht vor einem tiefgreifenden Wandel: Mit der DORA-Verordnung und der NIS2-Richtlinie hat die Europäische Union zwei zentrale…
Read More →
On November 4, 2025, the Director of the United States Patent and Trademark Office (USPTO) designated as precedential an appeals…
Read More →
Diagnostic errors are alarmingly common—and they can be extremely dangerous. According to Johns Hopkins Medicine, “[w]hile estimates vary, likely more…
Read More →
Extenuating circumstances may be present in both civil and criminal cases. In a criminal case, extenuating circumstances are factors present…
Read More →
Another campaign targeting WhatsApp users in Brazil spreads like a worm and employs multiple payloads for credential theft, session hijacking,…
Read More →